A change in the market - investing in diagnostics

被引：16

作者：

Batchelder, Keith ^{[1
]}

Miller, Peter ^{[1
]}

机构：

[1] Genom Healthcare Strategies, Charlestown, MA 02129 USA

来源：

NATURE BIOTECHNOLOGY | 2006年 / 24卷 / 08期

关键词：

D O I：

10.1038/nbt0806-922

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

Low margins, tricky reimbursement issues and the difficulty of market penetration have traditionally made diagnostics unattractive to investors. However, with changes to healthcare economics, regulation and the adoption of companion diagnostic tests that are predictive for drug response, that may be about to change. © 2006 Nature Publishing Group.

引用

页码：922 / 926

页数：5

共 4 条

[1] Forsman RW, 1996, CLIN CHEM, V42, P813
[2] A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients
Habel, Laurel A.
Shak, Steven
Jacobs, Marlena K.
Capra, Angela
Alexander, Claire
Pho, Mylan
Baker, Joffre
Walker, Michael
Watson, Drew
Hackett, James
T Blick, Noelle
Greenberg, Deborah
Fehrenbacher, Louis
Langholz, Bryan
Quesenberry, Charles P.
[J]. BREAST CANCER RESEARCH, 2006, 8 (03)
[3] Incidence of adverse drug reactions in hospitalized patients - A meta-analysis of prospective studies
Lazarou, J
Pomeranz, BH
Corey, PN
[J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (15): : 1200 - 1205
[4] Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients
Pirmohamed, M
James, S
Meakin, S
Green, C
Scott, AK
Walley, TJ
Farrar, K
Park, BK
Breckenridge, AM
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2004, 329 (7456): : 15 - 19

← 1 →